RiverPark Advisors LLC Purchases 3,305 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

RiverPark Advisors LLC lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 493.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,975 shares of the medical equipment provider's stock after buying an additional 3,305 shares during the quarter. RiverPark Advisors LLC's holdings in Lantheus were worth $356,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus in the third quarter worth $25,000. Kestra Investment Management LLC acquired a new stake in shares of Lantheus in the 4th quarter valued at about $27,000. Summit Securities Group LLC bought a new stake in Lantheus in the 4th quarter valued at about $37,000. UMB Bank n.a. raised its stake in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after buying an additional 134 shares during the period. Finally, Parkside Financial Bank & Trust raised its stake in Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after buying an additional 280 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Activity

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock valued at $6,016,046 in the last three months. Company insiders own 1.50% of the company's stock.

Lantheus Stock Down 1.8 %

NASDAQ:LNTH traded down $1.87 during trading hours on Friday, hitting $101.77. 644,509 shares of the company traded hands, compared to its average volume of 955,167. Lantheus Holdings, Inc. has a one year low of $65.76 and a one year high of $126.89. The company has a market cap of $6.97 billion, a PE ratio of 16.93 and a beta of 0.20. The firm's 50-day simple moving average is $97.37 and its 200-day simple moving average is $95.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LNTH. B. Riley decreased their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Truist Financial boosted their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and a consensus target price of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.